Phase I/II Trial of AGS-003

Article

Argos Therapeutics has begun a phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer. AGS-003 is a second-generation dendritic-cell-based therapy with optimized immune response characteristics designed to stimulate the immune system to target and destroy cancer cells.

DURHAM, North Carolina—Argos Therapeutics has begun a phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer. AGS-003 is a second-generation dendritic-cell-based therapy with optimized immune response characteristics designed to stimulate the immune system to target and destroy cancer cells.

Recent Videos
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Robert Califf, MD, MACC, a cardiologist and former FDA commissioner
Natalie Goedeker, CPNP, on Handling Neuromuscular Gene Therapy at Real-World Sites
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Michael Flanagan, PhD, chief scientific officer at Avidity
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Related Content
CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – April 4, 2025

Noah Stansfield
April 4th 2025
Article

Review top news and interview highlights from the week ending April 4, 2025.

ImmunoLogic

ImmunoLogic, Episode 2: "Charting New Frontiers in CAR T-Cell Safety" With Bruce Levine, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Noah Stansfield;Matt Hoffman
March 11th 2025
Podcast

In Episode 2 of ImmunoLogic, Bruce Levine, PhD, discussed the current the risk-benefit-ratio for CAR-T therapy.

European Medicines Agency Requests Pause on Trials for Sarepta’s DMD Gene Therapy Elevidys

European Medicines Agency Requests Pause on Trials for Sarepta’s DMD Gene Therapy Elevidys

Noah Stansfield
April 3rd 2025
Article

The move was made in relation to the previously-announced death of a US teenager who received the therapy.

ImmunoLogic

ImmunoLogic, Episode 1: "Chemo-Free Lymphoma? Seriously?" With Stephen J. Schuster, MD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Noah Stansfield;Matt Hoffman
January 31st 2025
Podcast

In Episode 1 of ImmunoLogic, Stephen J. Schuster, MD, discussed the potential of treating lymphoma without chemotherapy.

Data Roundup: March 2025 Features Updates from MDA's Conference, an Alzheimer Disease Trial, and More

Data Roundup: March 2025 Features Updates from MDA's Conference, an Alzheimer Disease Trial, and More

Noah Stansfield
April 1st 2025
Article

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

FDA Activity Recap: March 2025 Features FDA Approvals in Hemophilia, ATTR Amyloidosis, and More

FDA Activity Recap: March 2025 Features FDA Approvals in Hemophilia, ATTR Amyloidosis, and More

Noah Stansfield
April 1st 2025
Article

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

© 2025 MJH Life Sciences

All rights reserved.